Literature DB >> 35391818

Intermediate uveitis: Etiologies and outcomes in a tertiary referral hospital in KSA.

Haneen Al-Hujaili1,2, Khaled AlAbduljabbar3, Adel AlAkeely1, Hassan A Al-Dhibi1.   

Abstract

PURPOSE: The purpose of the study is to evaluate the common causes of intermediate uveitis (IU) and outcomes of this disease in patients presenting to King Khaled Eye Specialist Hospital (KKESH) in Riyadh, KSA.
METHODS: This retrospective cohort study evaluated medical files of patients with IU was reviewed. A total of 109 patients were included in the study. The diagnosis followed the Standardization of Uveitis Nomenclature criteria. Data analysis included personal data, etiology of IU, treatment, and complications.
RESULTS: We identified 109 patients with IU. The mean age at diagnosis was 26.45 ± 15.31 years. Most were female (64.9%), and 86% were bilateral at presentation. The etiology of IU was idiopathic in 63.3%. Multiple sclerosis (MS) (19.3%) and tuberculosis (14.7%) were frequent systemic causes of IU. The pattern of complications included macular edema (42.1%), cataract (48.2%), and secondary glaucoma (30.7%); 28.9% of the patients had none of the complications. Treatment comprised topical, local, and systemic steroids, immunosuppressive agents, and biologics. The best-corrected visual acuity was better than 20/40 in 57.5% of the eyes after more than 10 years of follow-up.
CONCLUSION: This study demonstrated that at KKESH, most of the IU cases were idiopathic or associated with MS and tuberculosis. Visual prognosis is favorable even with the long duration of IU and numerous complications. Copyright:
© 2022 Saudi Journal of Ophthalmology.

Entities:  

Keywords:  Complications; etiology; intermediate uveitis; systemic associations; treatment

Year:  2022        PMID: 35391818      PMCID: PMC8982936          DOI: 10.4103/1319-4534.337853

Source DB:  PubMed          Journal:  Saudi J Ophthalmol        ISSN: 1319-4534


  11 in total

1.  Patterns of Uveitis in a Tertiary Care Referral Institute in Saudi Arabia.

Authors:  Hassan A Al Dhibi; Hanan N Al Shamsi; Ammar M Al-Mahmood; Hassan M Al Taweel; Mohammed A Al Shamrani; J Fernando Arevalo; Vishali Gupta
Journal:  Ocul Immunol Inflamm       Date:  2016-02-24       Impact factor: 3.070

Review 2.  Intermediate uveitis.

Authors:  B Manohar Babu; S R Rathinam
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

3.  Clinical characteristics of intermediate uveitis in Chinese patients.

Authors:  Carmen K M Chan; Zenith H Y Wu; Fiona O J Luk; David T L Liu; Alex H Fan; Vincent Y W Lee; Timothy Y Y Lai
Journal:  Ocul Immunol Inflamm       Date:  2013       Impact factor: 3.070

4.  International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease.

Authors:  E Bloch-Michel; R B Nussenblatt
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

Review 5.  Global variation and pattern changes in epidemiology of uveitis.

Authors:  S R Rathinam; P Namperumalsamy
Journal:  Indian J Ophthalmol       Date:  2007 May-Jun       Impact factor: 1.848

6.  Pars planitis: a 20-year study of incidence, clinical features, and outcomes.

Authors:  Mark J Donaldson; Jose S Pulido; David C Herman; Nancy Diehl; David Hodge
Journal:  Am J Ophthalmol       Date:  2007-12       Impact factor: 5.258

7.  Intermediate uveitis: long-term course and visual outcome.

Authors:  N Vidovic-Valentincic; A Kraut; M Hawlina; S Stunf; A Rothova
Journal:  Br J Ophthalmol       Date:  2008-12-09       Impact factor: 4.638

Review 8.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

9.  Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center.

Authors:  Thomas Ness; Daniel Boehringer; Sonja Heinzelmann
Journal:  Orphanet J Rare Dis       Date:  2017-04-27       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.